The Sell-Side Weighs In: Was The Exact Sciences Sell-Off Overdone?
EXACT Sciences Corporation (NASDAQ: EXAS) stock tumbled nearly 10 percent Wednesday after the American Society of Clinical Oncology announced results from a new study on liquid biopsy tests for colorectal cancer that could pose a threat to EXACT’s Cologuard home screening test.
The new liquid biopsy test is up to 88 percent accurate, and co-author Ashish Nimgaonkar said more than 80 percent of patients who would prefer not to undergo a colonoscopy would also prefer a blood-based test to a stool-based test, according to the ASCO.
Clearly, the market sees the new test as bad news for EXACT, but here’s a sampling of what Wall Street analysts had to say Wednesday.
Voices From The Street
Baird analyst Catherine Ramsey Schulte said Thursday’s weakness seems overdone. “On first glance, what stands out to us is the fact that out of 620 subjects, 111 (18 percent) had pre-cancer and another 327 (53 percent) had cancer, which likely skews the specificity much higher than if the study were done on the typical U.S. population,” Schulte said.
Cowen analyst Doug Schenkel also used the word “overdone” to describe the market’s knee-jerk reaction. “The data looks interesting; however, this is a relatively small, single-site study that includes a disproportionate amount of diseased patients; there are also questions about study design,” he said.
Canaccord Genuity analyst Mark Massero said investors should be aggressively buying EXACT on the dip. “In our opinion, this study is apples-and-oranges different than EXAS' Deep-C Study, which got Cologuard approved by the FDA and into guidelines,” Massero said.
The new data also sparked a humorous Twitter debate between biotech expert Adam Feuerstein and QTR Research after QTR tweeted that EXACT shares “could honestly fall $10 on this news and still possibly be overvalued.”
Shortly after, QRT responded with a well-reasoned rebuttal.
Latest Ratings for EXAS
Nov 2017 | Leerink Swann | Maintains | Outperform | |
Nov 2017 | Baird | Downgrades | Outperform | Neutral |
Nov 2017 | BTIG Research | Downgrades | Buy | Neutral |
View More Analyst Ratings for EXAS
View the Latest Analyst Ratings
See more from Benzinga
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
